Submit Manuscript  

Article Details


An in silico immunogenicity analysis for PbHRH: an antiangiogenic peptibody by fusing HRH peptide and human IgG1 Fc fragment

Author(s):

Lin Ning, Bifang He, Juanjuan Kang and Jian Huang *  

Abstract:


Eptibodies which fuse peptides and antibodies, represent a novel strategy in therapeutic use. Previously, we computationally designed an antiangiogenic peptibody drug PbHRH, which fused the HRH peptide with angiogenesis-suppressing effect and human IgG1 Fc fragment using Romiplostim as template. Molecular modelling and simulation results indicated that it would be a potential drug for the treatment of those angiogenesis related pathological disorders. However, its immunogenicity is not known.Several bioinformatics tools are used to predict the immunogenicity of PbHRH and Romiplostim is the control.IEDB recommended method is used in MHC-I and MHC-II binding prediction, and the IEDB web server (http://tools.iedb.org/immunogenicity/) is used to determine the immunogenicity of each piptide. Several peptides are predicted to have the potential ability to bind to MHC-I and MHC-II molecules both in PbHRH and Romiplostim. Most of these selected peptides are exactly the same. Allele frequency analysis shows a low population distribution. Combined with the MHC-I immunogenicity prediction, both of HRH and PbHRH have low immunogenicity. Herein,We formed a strategy to predict and analyze the immunogenicity of protein or peptide drugs for the future improvement.

Keywords:

immunogenicity prediction, PbHRH, peptibody, peptide , human IgG1 Fc, fragment

Affiliation:

Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu, P.R. , Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu, P.R. , Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu, P.R. , Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu, P.R.



Full Text Inquiry